

George W Creasy

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5575957/george-w-creasy-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

24
papers

2,296
citations

19
h-index

24
g-index

24
ext. papers

2,597
ext. citations

2
avg, IF

4.07
L-index

#	Paper	IF	Citations
24	Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.. <i>PLoS ONE</i> , 2022 , 17, e0261775	3.7	1
23	Vaginal progesterone is as effective as cervical cerclage to prevent preterm birth in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix: updated indirect comparison meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2018 , 219, 10-25	6.4	65
22	Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. <i>American Journal of Obstetrics and Gynecology</i> , 2018 , 218, 161-180	6.4	203
21	In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5459-66	5.9	9
20	Vaginal progesterone vs. cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. <i>American Journal of Obstetrics and Gynecology</i> , 2013 , 208, 42.e1-42.e18	6.4	103
19	490: Two year infant outcomes for children exposed to supplemental intravaginal progesterone gel in utero: secondary analysis of a multicenter, randomized, double-blind, placebo-controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2012 , 206, S223	6.4	14
18	Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. <i>American Journal of Obstetrics and Gynecology</i> , 2012 , 206, 124.e1-19	6.4	335
17	Conception rates in clomiphene citrate cycles with and without hormone supplementation: a pilot study. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1035-40	2.5	7
16	The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. <i>Contraception</i> , 2004 , 69, 189-95	2.5	95
15	Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. <i>Fertility and Sterility</i> , 2003 , 80, 34-42	4.8	54
14	Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. <i>Contraception</i> , 2003 , 67, 93-9	2.5	27
13	Transdermal contraception: evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. <i>American Journal of Obstetrics and Gynecology</i> , 2002 , 186, 15-20	6.4	44
12	Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. <i>Fertility and Sterility</i> , 2002 , 77, S32-5	4.8	155
11	Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. <i>Fertility and Sterility</i> , 2002 , 77, S27-31	4.8	90
10	A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). <i>Fertility and Sterility</i> , 2002 , 77, S19-26	4.8	73
9	Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. <i>Fertility and Sterility</i> , 2002 , 77, S13-8	4.8	208
8	Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. <i>Journal of Clinical Pharmacology</i> , 2001 , 41, 1301-9	2.9	40

7	Transdermal contraception. <i>Seminars in Reproductive Medicine</i> , 2001 , 19, 373-80	1.4	12
6	Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. <i>Contraception</i> , 2001 , 63, 289-95	2.5	37
5	Efficacy and safety of a transdermal contraceptive system. <i>Obstetrics and Gynecology</i> , 2001 , 98, 799-805	4.9	60
4	Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. <i>American Journal of Obstetrics and Gynecology</i> , 2000 , 182, 1184-90	6.4	122
3	An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. <i>American Journal of Obstetrics and Gynecology</i> , 2000 , 182, 1173-83	6.4	257
2	The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. <i>American Journal of Obstetrics and Gynecology</i> , 1994 , 170, 474-8	6.4	161
1	Endometrial morphology in asymptomatic postmenopausal women. <i>American Journal of Obstetrics and Gynecology</i> , 1991 , 165, 317-20; discussion 320-2	6.4	124